Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava has received the go-ahead from the FDA to initiate two pivotal trials of its Alzheimer's therapy Simufilam. One week ago, however, a citizen's petition filed with the FDA insisted that data from earlier studies of Simufilam had been manipulated in various ways.

Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor

Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.

Cassava (SAVA) Responds to Charges Against its Integrity in AD Study

Palantir Technologies

StoneCo

Worried investors have been panic selling stocks that are worthwhile investments. Here are three stocks to buy to take advantage of that.

3 Underpriced Stocks to Buy Before a Federal Reserve Taper

Wall Street is notorious for its overreactions, but when it comes to SAVA stock's cratering, investors consider other historical precedents. The post Why Traders Shouldn't Bargain Hunt in Cassava Stock appeared first on InvestorPlace.

Why Traders Shouldn't Bargain Hunt in Cassava Stock

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) resulting from allegations that Cassava Sciences may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cassava Sciences securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – SAVA

This once-promising biotech is now struggling to stay afloat.

As Allegations Swirl, Can Investors Still Count on Cassava Sciences Stock?

Cassava Sciences Inc (NASDAQ:SAVA) is up 4.1% at $84.16 this morning, in an attempt to bounce back from yesterday's news that its Alzheimer's drug was facing scrutiny.

Biotech Stock Tries to Recover as Alzheimer's Drug Draws Questions

Annovis Bio

It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment.

Better Biotech Stock: Cassava Sciences vs. Annovis Bio

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit

Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 25, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).If you suffered losses exceeding $50,000 investing in Cassava stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...

Cassava Investor Alert

Today, investors in Cassava Sciences and SAVA stock are seeing a lot of red, as investors digest a statement of concern filed yesterday. The post SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations appeared first on InvestorPlace.

SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations

Atlanta, Georgia--(Newsfile Corp. - August 25, 2021) - Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) complied with federal securities laws. On August 24, 2021, it was revealed that a Citizen Petition had been filed with the FDA, questioning the quality and integrity of the Company's research and data, suggesting the data had been manipulated. The Petition further sought a halt to Cassava's current clinical...

SHAREHOLDER ALERT: Investigation of Cassava Sciences, Inc. Announced by Holzer & Holzer, LLC

BioLife Solutions

Don't let these companies fly under your radar.

2 Little-Known Nasdaq Stocks Making Big Moves Wednesday

Shares of SAVA stock are crashing on Wednesday after allegations about Cassava Sciences' Alzheimer's disease treatment are being reviewed. The post SAVA Stock: The Allegations That Have Cassava Sciences Sinking Today appeared first on InvestorPlace.

SAVA Stock: The Allegations That Have Cassava Sciences Sinking Today

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

The FDA received a citizen petition requesting a halt to clinical trials with the company's Alzheimer's disease candidate.

Here's Why Cassava Sciences Is Having a Bad Day

LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - August 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. On August 25, 2021, Bloomberg reported that shares of Cassava were down over 20% in pre-market trading "after a lawyer asked the FDA to halt the company's clinical trials of an experimental drug, citing concerns about the...

Shareholder Alert: Berman Tabacco Announces Investigation of Cassava Sciences, Inc. (SAVA) for Potential Securities Law Violations

GameStop

NuCana

Electrameccanica

trivago

Verb Technology Company Inc

Alkaline Water Company Inc (The)

The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalysts appeared first on InvestorPlace.

7 Bargain Stocks to Buy Under $5 With the Right Catalysts

Cassava Sciences Inc (NASDAQ: SAVA) reached an SPA (Special Protocol Assessment) agreement with the U.S. FDA on Tuesday morning for the phase 3 trial of its Alzheimer's treatment, Simufilam. Shares of the company, however, tanked about 30% this morning on a statement of concern that raised a question on the integrity of western blot analyses […] The post Here's why Cassava Sciences stock tanked 30% Wednesday morning appeared first on Invezz.

Here's why Cassava Sciences stock tanked 30% Wednesday morning

SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam. The post Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near appeared first on InvestorPlace.

Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near

Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced an agreement with the Food and Drug Administration regarding two late-stage studies of its lead drug candidate simufilam in Alzheimer's disease.

Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower on negative claims that were posted online yesterday after market hours. The company issued a response to the claims today, saying they believe the claims regarding scientific integrity are false and misleading.

Why Cassava Sciences' Stock Is Getting Hammered Today

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 20% pre-market. This is why it happened.

SAVA Stock: Over 20% Decrease Pre-Market Explanation

Cassava Sciences Inc. SAVA, +1.92% responded Wednesday to allegations posted overnight regarding the "accuracy and integrity" of trial data for its treatment of Alzheimer's disease, saying it believed the claims are "false and misleading." Cassava's stock had rallied 1.9% on Tuesday, and 16.4% over the past three days, with the company saying early Tuesday that it reached agreement with the Food and Drug Administration under a Special Protocol Assessment (SPA) for its Phase 3 studies of oral simufilam for the treatment of Alzheimer's patients.

News for Cassava Sciences Inc Stock (SAVA)